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Abstract
Flavin-containing monooxygenases (FMO) are metabolic enzymes mediating the oxygenation of nucleophilic atoms such as nitrogen, sulfur, phosphorus and selenium. These enzymes share similar properties to the cytochrome P450 (CYP) system but can be differentiated through heat inactivation and selective substrate inhibition by methimazole. This study investigated 10 compounds with varying degrees of FMO involvement to determine the nature of the correlation between human invitro and in-vivo unbound intrinsic clearance. In order to confirm and quantify the extent of FMO involvement 6 of the compounds were investigated in human liver microsomal (HLM) in vitro assays using heat inactivation and methimazole substrate inhibition. Under these conditions FMO contribution varied from 21% (imipramine) to 96% (itopride). Human hepatocyte and HLM intrinsic clearance (CLint) data was scaled using standard methods to determine the predicted unbound intrinsic clearance (predicted CLint u) for each compound. This was compared with observed unbound intrinsic clearance (observed CLint u) values back calculated from human pharmacokinetic studies. A good correlation was observed between the predicted and observed CLint u using hepatocytes (R 2 = 0.69) with 8 out of the 10 compounds investigated within or close to a factor of 2.
For HLM the in vitro-in vivo correlation was maintained (R 2 = 0.84) but the accuracy was reduced with only 3 out of 10 compounds falling within, or close to, 2-fold. This study demonstrates that human hepatocytes and HLM can be used with standard scaling approaches to predict the human in vivo clearance for FMO substrates.
Introduction
Flavin-containing monooxygenase (FMO) are a major enzyme system mediating oxygenation of nucleophilic atoms typically nitrogen, sulfur, phosphorus and selenium. FMOs have an important role in the metabolism of exogenous compounds including many drugs but also endogenous compounds such as trimethylamine (Phillips and Shephard, 2008) . These enzymes are similar to cytochrome P450s (CYPs) in cellular location and cofactor requirement (oxygen and NADPH).
However, FMOs can be differentiated from CYPs by heat inactivation (maximum of 5 minutes at 40
to 50 o C in the absence of NADPH) and inhibition by specific competitive substrate inhibitors such as methimazole (Cashman and Zhang, 2006; Taniguchi-Takizawa et al., 2015) .
There are 5 FMOs expressed in human with the major hepatic enzyme being FMO3 which is regarded as having the greatest role in drug metabolism. FMOs are also expressed in extrahepatic tissue including lung and kidney with FMO1 the major form expressed in kidney and FMO2 mainly expressed in the lung (Cashman and Zhang, 2006) . However, in studies which use hepatocytes and human liver microsomes (HLM) only, clearance by FMO may be underestimated due to the lack of expression of FMO1 and 2 in human liver.
Along with differential tissue distribution, the FMOs also have differing substrate specificity. For instance, the FMO1 active site is reported to accommodate larger tertiary amines and sulfurcontaining substrates such as imipramine and chlorpromazine (Kim and Ziegler, 2000) . This is supported by studies on tamoxifen (Parte and Kupfer, 2005) which show a higher rate of metabolism in FMO1 vs FMO3. In contrast ranitidine shows a higher rate for both the N and S-oxygenations in FMO3 vs FMO1 (Chung et al., 2000) . FMO3 has been shown to metabolise many primary, secondary and tertiary amines along with various sulfur-containing substrates and is viewed as the principal (Geier et al., 2015) . Little is known about the substrate specific for FMO4 because the protein is unstable. Finally, FMO5, which is expressed at similar levels to FMO3 in the liver (Cashman and Zhang, 2006) , shows little reported activity toward drug like molecules (Krueger et al., 2006) although it has been shown that the purified enzyme can carry out BaeyerVilliger reactions (Fiorentini et al., 2016) .
For drugs undergoing oxygenation by FMOs it is important to be able to quantify their contribution to metabolism and clearance in order to be able to assess the impact on drug-drug interaction (DDI)
profile. When FMO is contributing to metabolism this may serve to mitigate DDIs from other enzymes such as the CYPs impacting the overall DDI profile of the drug.
The ability to predict the in vivo clearance (CL) of compounds is a key part of drug metabolism activities. The methods by which clearance is predicted differ depending on the route of elimination e.g. renal, hepatic etc. (Di et al., 2013; Grime et al., 2013) . The method most routinely used for hepatic metabolic clearance is scaling the unbound intrinsic clearance (CLint u) from in vitro systems.
Hepatocytes or HLM Clint U values are scaled to the in vivo situation using factors for the number of cells or milligram protein per g liver and the ratio of liver weight to body weight and then applying the well-stirred model (Riley et al., 2005; Di et al., 2013) . The observation that these in vitro systems can produce systematic under prediction of in vivo CL can be addressed by use of a regression offset method as described previously (Grime and Riley, 2006) . However, although this approach generally works well for CYP it has also been shown not to work well for other enzymes substrates such as aldehyde oxidase (AO) where the in vitro data produces a significant under predication of the in vivo CL (Zientek et al., 2010 (Zientek et al., ). et al., 2002 . In this study rat and human hepatocytes were used to predict in vivo blood clearances (CLb) using the scaling methodology described above. In this case the in vivo CL in rat was predicted well from the in vitro CLint (within 30% of the measured value) whereas there was an over prediction of the human CL (>10.5 vs 2.4ml/min/kg). However, this is for only one compound and to date there has not been a comprehensive assessment of FMO scaling using a series of substrates with differing FMO contributions.
The aim of this study was to use human in vitro data to predict the CL for a set of compounds for which all or part of the in vivo CL has been determined to be mediated by FMO.
the internal standard peak area against time. CLint values were then calculated from the negative slope of the linear fit divided by the microsomal concentration.
Hepatocytes Clint incubations:
The hepatocytes were thawed and re-suspended in pre-warmed L-15 medium to give a concentration of 1.0 × 10 6 viable cells/mL (>80% viability). The incubations were performed in duplicate in a 96-well plate and the reaction initiated by addition of the compound in ACN (less than 1% final concentration) to give a final concentration of 1µM. The plate was incubated at 37 °C and 20µl samples removed at 0. 5, 5, 15, 30, 45, 60, 80 , 100 and 120 minutes and added to 100 µL of cold ACN (containing internal standard). The samples were then centrifuged at 4000 rpm and 4°C for 20 minutes before quantitation using LC-MS/MS. The kinetic data were analyzed using a linear fit of the natural logarithm of the ratio of the compound peak area to the internal standard peak area against time. CLint values were then calculated from the negative slope of the linear fit divided by the number of hepatocytes.
HµREL low CLint incubations:
If the hepatocyte CLint was less than 1µl/min/million cells then a low intrinsic clearance assay using the HμREL primary human hepatocyte co-culture system was used. This methodology has been described in detail previously (Bonn et al., 2016) . Briefly, co-culture plates at a seeding density of 30,000 hepatocytes per well were shipped in HµREL PlatinumHeps shipping medium, at 37 o C, from HµREL (North Brunswick, NJ, USA). On arrival the shipping medium was replaced with PlatinumHeps maintenance medium and the cells left to acclimatize overnight in incubator at 37 o C in humidified atmosphere containing 95% air and 5% CO2. Prior to the incubation the cells in each well were washed with 100µl HµREL PlatinumHeps dosing medium which was aspirated and replaced with 50µl of fresh media prior to the addition of the test compound which was added in 50µl HµREL PlatinumHeps dosing medium (final concentration 1μM with less than 1% ACN). Samples (45µl) were taken at 6 time points (1, 3, 5, 24, 48 and 70 hours) and added to 180µl ice cold acetonitrile. Samples were centrifuged (20 minutes 4°C, 4000g) and 50µl of the supernatant was diluted within 100µl water prior to LC-MS/MS analysis. The kinetic data were analyzed using a linear fit of the natural logarithm of the compound peak area against time. CLint values were then calculated from the negative slope of the linear fit divided by the hepatocyte concentration. 
HLM Incubations for determination of FMO contribution:

Determination of unbound fraction in human plasma (fu):
The extent of binding of compounds to plasma proteins was determined by equilibrium dialysis at a compound concentration of 5μM using the Rapid Equilibrium Device (RED Thermoscientific Pierce). Phosphate buffer (100mM pH 7.4) was added to the buffer chamber, and 300μl of plasma with compound to the sample chamber. The unit was covered with a gas permeable lid and incubated for 18 hours at 37°C at 300 rpm with 5% CO2.
At the end of incubation, samples (50μl) from both buffer and plasma chambers were removed for analysis. Samples and standards were matrix matched and analysed using LC-MS/MS. The unbound fraction in plasma (fu) was calculated as follows: fu = Conc. buffer chamber / Conc. plasma chamber
Determination of unbound fraction in HLM (fu inc):
The extent of binding of compounds to HLM was determined by equilibrium dialysis using the HTDialysis LLC device (Gales Ferry, CT) with HLM at a concentration of 1mg/ml and a final compound concentration of 1μM. PBS (150μl) was added to the buffer well and 150μl HLM containing the compound to the sample well and incubated at 37°C
for 4 hours. After the incubation, 50μl aliquots from both donor and receiver wells were removed for analysis. Samples and standards were matrix matched and analysed by LC-MS/MS. The unbound fraction in the incubation (fu inc) was calculated as follows:
fu inc = Conc. buffer well / Conc. microsomal suspension well
Determination of unbound fraction in rat hepatocytes (fu inc).
The extent of binding of compounds to rat hepatocytes was also determined by equilibrium dialysis using the HTDialysis LLC device (Gales Ferry, CT). Rat Hepatocytes were re-suspended with pre-warmed L-15 medium at 1.0 × 10 6 viable cells/ml. The test compounds, at a final concentration of 1μM, were added to the hepatocyte suspension. 150 μl of the hepatocytes suspension containing the compound was added to each of
Unbound intrinsic clearance calculations
In vitro: The unbound in vitro CLint (Clint u) using hepatocytes or microsomes were compared with the in vivo CLint u values using the regression scaling method (Grime and Riley, 2006) . Briefly, the unbound intrinsic clearance was determined using the following equation:
Predicted CLint u = ((CLint/fu inc) x SF1 x SF2) X 3 /1000 (1) where SF1 is the scaling factor for the number of cells per gram of liver (120x10 6 cells/g for human)
or the milligrams of microsomal protein per gram of liver (40mg/g for human), SF2 is the scaling factor for the liver to body weight ratio (24g/kg for human) and fu inc is the unbound fraction in the incubation. Note the unbound CLint is multiplied by 3 by way of applying the regression offset correction. Blood clearance (CLb) was calculated using the well stirred model in the following equation:
In vivo: The in vivo, observed, unbound intrinsic clearance was calculated from the in vivo plasma clearance values by back calculating through the well stirred liver model using the following equation:
This article has not been copyedited and formatted. The final version may differ from this version. is the renal clearance, Q is hepatic blood flow (23ml/min/kg in human), fu is the plasma protein binding and Rb/p is the blood/plasma ratio. When using the oral clearance values it is assumed that the compound is completely absorbed and that the liver is the major organ of clearance.
For this study 10 compounds were selected from the literature where the metabolism has been shown to involve FMO: benzydamine (Taniguchi-Takizawa et al., 2015) , imipramine (Adali et al., 1999) , olanzapine (Korprasertthaworn et al., 2015) , ranitidine (Chung et al., 2000) , cimetidine (Cashman et al., 1993) , moclobemide (Hoskins et al., 2001) This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Determination of FMO involvement
The contribution of FMO to the intrinsic clearance in HLM was determined using a combination of methimazole competitive substrate inhibition and heat inactivation (Taniguchi-Takizawa et al., 2015) . The results of these studies are illustrated in fig. 2 .
The overall FMO contribution was defined as the mean of the inhibition by the competing substrate methimazole (500µM) and the extent of heat inactivation. Both mechanisms give a broadly similar extent of reduction of FMO activity (greater than 80% reduction) as determined by benzydamine Noxide formation. Under the same conditions there was minimal impact (less than 30% reduction in activity) on CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A. The impact on CYP1A2 was more significant with 37% reduction in activity in the presence of methimazole but only 12% reduction by heat inactivation (for full methods and results see supplemental data).
It was not possible to determine the FMO contribution for ranitidine, cimetidine, olanzapine and tamoxifen due to the low intrinsic clearance (< 3µl/min/mg) observed in this study ( fig. 2) . However, amongst the remaining 6 compounds the greatest FMO contribution was observed with itropride (>90% FMO) and the lowest was imipramine (~20% FMO). Benzydamine had an FMO contribution of 53%, moclobemide and tozasertib both had a contribution of 38% and clozapine had a contribution of 23%.
Human in vivo studies
This article has not been copyedited and formatted. The final version may differ from this version. The 10 FMO substrates with human pharmacokinetic data. ( fig. 1) were identified from the literature. The plasma clearance data for these compounds was combined with the measured plasma protein binding and blood/plasma ratio (Rb/p) to derive the observed unbound CLint as described in the materials and methods (table 2) .
The only compounds in the set with reported significant renal clearance were ranitidine and cimetidine with renal clearances of 7.4 and 6.7ml/min/kg respectively (Walkenstein et al., 1978; van Hecken et al., 1982) . This was incorporated into the calculations and the derived hepatic clearance used to calculate the unbound CLint as detailed in the methods section. The resulting metabolic component of clearance was calculated to be 1.8ml/min/kg for ranitidine and 2ml/min/kg for cimetidine (table 2) .
For olanzapine, itopride, clozapine and tamoxifen no human intravenous data was available. For these compounds it was assumed that absorption was complete and that the liver is the major organ of clearance such that the observed oral clearance approximates to the intravenous clearance. This resulted in clearance values of 13.9, 7.6 and 19ml/min/kg respectively.
Human in vitro studies
The in vitro CLint was determined for the 10 FMO substrates in human hepatocytes and HLM at a substrate concentration of 1µM. The hepatocyte and HLM CLint values ranged from 0.1µl/min/million cells and <0.3µl/min/mg respectively for cimetidine to 29.2µl/min/million cells and 64.5µl/min/mg respectively for tozasertib.
The predicted unbound CLint was derived by combining the CLint with the measured fraction unbound in the incubation and applying the regression correction (table 3 & 
equation 1).
This article has not been copyedited and formatted. The final version may differ from this version. For olanzapine, ranitidine and cimetidine the HLM CLint was beyond the limit of the assay (<3µl/min/mg protein) so a conservative value of 3µl/min/mg protein was used in the subsequent calculations.
The HLM CLint u values were on average 1.7-fold high than the hepatocyte values although this was influenced by inclusion of olanzapine, ranitidine and cimetidine which had HLM Clint values set to 3 µl/min/mg. If these three compounds are omitted from the analysis the then this drops to 0.8-fold so the unbound CLints from both systems compare very favourably.
Comparison of predicted and observed unbound intrinsic clearance
The Clint u was calculated for each compound from the hepatocyte or HLM in vitro CLint and compared with the corresponding value calculated from CL values from intravenous or, if no intravenous study was available, from an oral study assuming a value for the bioavailability. The resulting Clint u values were then compared for each of the systems studied ( Fig. 3 A and B and Fig. 4 A and B).
Human hepatocytes produced a good concordance (R 2 = 0.69) between the predicted and observed unbound intrinsic clearance values with 8 out of 10 compounds falling within or very close to 2-fold of the line of unity ( fig. 3A) . There was also a strong correlation between predicted and observed CLb with an R 2 of 0.75 ( fig. 3B ). Benzydamine showed approximately 6-fold over prediction in terms of CLint u (predicted CLint u = 104ml/min/kg vs. observed CLint u = 18ml/min/kg) which in turn equates to approximately a 4-fold over prediction in blood clearance (predicated CLb 11ml/min/kg vs observed CLb 3ml/min/kg). This is a similar degree of over prediction observed previously (Fisher et al., 2002) . In contrast, tozasertib showed an under prediction of around 3 fold in CLint u (predicted 
Discussion
The prediction of human pharmacokinetics is an important part of drug discovery. The use of human in vitro systems such as hepatocytes or HLM combined with the appropriate scaling factors have been routinely used to predict human in vivo CL (Riley et al., 2005; Di et al., 2013) .
It has been shown that not all enzyme systems are fully recovered when the in vitro preparation is produced from the original tissue. Specifically, AO activity has been shown to be lower in isolated in vitro systems compared to the original tissue (Hutzler et al., 2014) . This reduced activity significantly impaired the ability of these in vitro systems to adequately predict the clearance of a set of AO substrates (Zientek et al., 2010) . The current study determined the in vitro CLints in hepatocytes and HLM for a set compounds which had differential degrees of FMO involvement in their metabolism.
The aim was to determine whether FMOs were subject to similar recovery issues as AO and the potential downstream consequences for the prediction on in vivo CL.
The 10 compounds used here have all been shown to have metabolic routes that are mediated by FMO. Generally, FMO investigations have been related to specific metabolic pathways such as the Noxygenation of moclobemide (Hoskins et al., 2001) without necessarily looking at the contribution the pathway makes to the overall hepatic in vitro CLint. When this was determined for 6 of the 10 FMO substrates in this study the FMO contribution was seen to vary from itopride (>90%) to imipramine and clozapine where the FMO contribution is just over 20%. This reflects the situation seen in many drug discovery programs where the contribution to hepatic metabolism for any given enzyme will vary across compounds.
This article has not been copyedited and formatted. The final version may differ from this version. It has been argued that hepatocytes are the most suitable system to use for scaling clearance because of the presences of the full complement of drug metabolising enzymes (Riley et al., 2005 ).
This aspect is important for compounds such as olanzapine which have been shown to form phase 2 metabolites such as N-glucuronides which would not be seen and so accounted for in the HLM (Korprasertthaworn et al., 2015) . Interestingly, in this study olanzapine predicted clearance equally well from both hepatocytes and HLM suggesting that the N-glucuronide is not playing a major role in the rate of metabolism in these systems.
The only compound that was significantly over predicted in both hepatocyte and HLM was benzydamine. This was also the case in HLM. This was observed previously by Fisher et al (2002) who speculated that the reported intravenous human pharmacokinetics may be in error possibly due to enterohepatic re-cycling of the N-oxide metabolite, an analytical error or an unknown enhancement of FMO activity in the in vitro systems. The potential for the N or S-oxide to be reduced back to the original drug molecule in vivo which would confound this type of in vitro-in vivo assessment and lead to an under prediction of in vivo CLint. It has been shown that both imipramine and desipramine are circulating in the plasma of healthy volunteers following intravenous, intra muscular and oral dosing of imipramine N-oxide (Nagy and Hansen, 1978) . Whether one of these reasons or a different reason is behind the under-prediction of benzydamine is unclear.
FMOs are differentially distributed in the body with FMO3 and FMO5 expressed in the liver and FMO1 and FMO2 mainly expressed in the kidney and lung respectively (Cashman and Zhang, 2006) .
Hence, studies that use human hepatocytes and HLM will reflect the involvement of FMO3, and to a lesser extent FMO5, but not FMO1 and FMO2. As such these studies may underestimate the contribution of FMO to the overall clearance of a compound if the latter two enzymes play a significant role in its metabolism. However, based on the S-oxygenation of a disulfiram metabolite, it
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at ASPET Journals on November 6, 2017 dmd.aspetjournals.org has been estimated that the human kidney has 14-fold lower FMO metabolic capacity compared to the liver so the impact of FMO1 may not be highly significant (Cashman and Zhang, 2006) .
In general HLM did not perform as well as hepatocytes in predicting CLb in this study supporting the view that the intact hepatocyte is a better system for predicting human clearance. There were a number of compounds that were both over and under predicted. The reason for this is not clear but may relate to other clearance mechanisms not reflected in HLM or low recovery of the microsomal clearance enzymes after cryopreservation.
The approach adopted in this study uses point estimates for the scaling factors -the number of cells per gram of liver or the milligrams of microsomal protein per gram of liver and the liver to body weight ratio. This does not take into account the population variability in these scaling factors which in turn can lead to variability in the subsequent clearance estimates (Kenyon et al., 2016) . However, in the context of drug discovery where the challenge is to optimise and select a small number of drug molecules from 100s of compounds it can be argued that using such point estimates can facilitate this selection because it reduces the number of parameters contributing to the overall variability to those related to the molecule and not to system. Whilst this allows rank ordering of compounds it does not give a full understanding of the variability in clearance that might occur in vivo. Once compounds are selected then it is appropriate to use more sophisticated approaches such as physiologically based pharmacokinetic (PBPK) modelling to account for variability in these scaling factors along with the variability in other system related parameters such as the variability in the enzyme expression. This is also important for FMO3 in particular given the polymorphic nature of its expression (Cashman and Zhang, 2006) . At this stage it is important to consider the variability that might be seen in pediatric populations as it is reported that FMO1 is expressed in the liver up to 72
hours postnatally when it is suppressed whilst FMO3 expression increases in a variable manner until full expression is reached around 10 years of age (Hines and McCarver, 2002 Legends for Figures   Fig. 1 Structures of the 10 FMO substrates used in the current study All data n = 3 except for data marked with * which is n = 2 a Data from rat hepatocytes 
